Indeed, two previous studies have used ADC versions of two other LGR5 antibodies for killing LoVo cells in vitro and targeting the LoVo cell tumour model in vivo (Junttila et al, 2015; Gong et al, 2016). The gene discussed is LGR5; the disease is neoplasm.